Movement Alert｜Krystal Biotech Inc. Rises 6.36% in Pre-Market Trading, Strong Q2 Earnings Expectations and S&P MidCap 400 Inclusion Drive Momentum

Market Focus

Jul 29

On July 29, Krystal Biotech Inc. rose 6.36% in pre-market trading, trading at $387.38/share, with turnover of $41,300.

On the news front, the company is set to report Q2 earnings on August 3 before market open, with consensus estimates projecting revenue of $122 million (up 32.72% year-over-year), adjusted EPS of $1.69 (up 49.59%), and EBIT growth of 88.66%. The strong outlook follows a significant Q1 beat, where EPS came in at $1.83 versus the FactSet estimate of $1.44, prompting multiple analysts to raise forecasts.

Additionally, Krystal Biotech was recently added to the S&P MidCap 400 index, replacing Taylor Morrison Home, which is being acquired by Berkshire Hathaway. Index inclusion typically drives passive fund inflows. On the fundamental side, the company's core product Vyjuvek secured UK MHRA approval for treating dystrophic epidermolysis bullosa, expanding its international commercial footprint.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1173591978"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1173591978\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1173591978?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-29 16:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173591978","market":"us","top_or_hot":-1,"title":"Movement Alert｜Krystal Biotech Inc. Rises 6.36% in Pre-Market Trading, Strong Q2 Earnings Expectations and S&P MidCap 400 Inclusion Drive Momentum","media":"Market Focus","content":"<p><p>On July 29, Krystal Biotech Inc. rose 6.36% in pre-market trading, trading at $387.38/share, with turnover of $41,300.</p><p>On the news front, the company is set to report Q2 earnings on August 3 before market open, with consensus estimates projecting revenue of $122 million (up 32.72% year-over-year), adjusted EPS of $1.69 (up 49.59%), and EBIT growth of 88.66%. The strong outlook follows a significant Q1 beat, where EPS came in at $1.83 versus the FactSet estimate of $1.44, prompting multiple analysts to raise forecasts.</p><p>Additionally, Krystal Biotech was recently added to the S&P MidCap 400 index, replacing Taylor Morrison Home, which is being acquired by Berkshire Hathaway. Index inclusion typically drives passive fund inflows. On the fundamental side, the company's core product Vyjuvek secured UK MHRA approval for treating dystrophic epidermolysis bullosa, expanding its international commercial footprint.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Krystal Biotech Inc. Rises 6.36% in Pre-Market Trading, Strong Q2 Earnings Expectations and S&P MidCap 400 Inclusion Drive Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Krystal Biotech Inc. Rises 6.36% in Pre-Market Trading, Strong Q2 Earnings Expectations and S&P MidCap 400 Inclusion Drive Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-29 16:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 29, Krystal Biotech Inc. rose 6.36% in pre-market trading, trading at $387.38/share, with turnover of $41,300.</p><p>On the news front, the company is set to report Q2 earnings on August 3 before market open, with consensus estimates projecting revenue of $122 million (up 32.72% year-over-year), adjusted EPS of $1.69 (up 49.59%), and EBIT growth of 88.66%. The strong outlook follows a significant Q1 beat, where EPS came in at $1.83 versus the FactSet estimate of $1.44, prompting multiple analysts to raise forecasts.</p><p>Additionally, Krystal Biotech was recently added to the S&P MidCap 400 index, replacing Taylor Morrison Home, which is being acquired by Berkshire Hathaway. Index inclusion typically drives passive fund inflows. On the fundamental side, the company's core product Vyjuvek secured UK MHRA approval for treating dystrophic epidermolysis bullosa, expanding its international commercial footprint.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KRYS","symbol_name":"Krystal Biotech Inc.","start_time":0,"source_url":"","article_id":"1173591978","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173591978","pubTimestamp":1785315558,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 29, Krystal Biotech Inc. rose 6.36% in pre-market trading, trading at $387.38/share, with turnover of $41,300.On the news front, the company is set to report Q2 earnings on August 3 before...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KRYS":"Krystal Biotech Inc."},"translate_title":"走势警报|Krystal Biotech Inc. 在盘前交易中上涨 6.36%，强劲的第二季度盈利预期和标准普尔中型股 400 指数的纳入推动了动力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KRYS":1},"content_text":"On July 29, Krystal Biotech Inc. rose 6.36% in pre-market trading, trading at $387.38/share, with turnover of $41,300.On the news front, the company is set to report Q2 earnings on August 3 before market open, with consensus estimates projecting revenue of $122 million (up 32.72% year-over-year), adjusted EPS of $1.69 (up 49.59%), and EBIT growth of 88.66%. The strong outlook follows a significant Q1 beat, where EPS came in at $1.83 versus the FactSet estimate of $1.44, prompting multiple analysts to raise forecasts.Additionally, Krystal Biotech was recently added to the S&P MidCap 400 index, replacing Taylor Morrison Home, which is being acquired by Berkshire Hathaway. Index inclusion typically drives passive fund inflows. On the fundamental side, the company's core product Vyjuvek secured UK MHRA approval for treating dystrophic epidermolysis bullosa, expanding its international commercial footprint.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}